Burns J W & Co. Inc. NY trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 26,666 shares of the biopharmaceutical company’s stock after selling 1,597 shares during the period. Burns J W & Co. Inc. NY’s holdings in Gilead Sciences were worth $1,910,000 at the end of the most recent quarter.
Other institutional investors have also modified their holdings of the company. Welch Investments LLC acquired a new stake in Gilead Sciences during the 3rd quarter worth about $108,000. Wealthcare Advisory Partners LLC acquired a new stake in Gilead Sciences during the 3rd quarter worth about $133,000. Horan Capital Advisors LLC. acquired a new stake in Gilead Sciences during the 3rd quarter worth about $144,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Gilead Sciences during the 2nd quarter worth about $147,000. Finally, Hanson & Doremus Investment Management boosted its position in shares of Gilead Sciences by 806.5% during the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 1,613 shares in the last quarter. Hedge funds and other institutional investors own 75.71% of the company’s stock.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at $80.70 on Tuesday. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.48 and a current ratio of 3.55. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $89.54. The stock has a market cap of $105,390.00, a P/E ratio of 23.19, a PEG ratio of -1.85 and a beta of 1.22.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be paid a dividend of $0.57 per share. The ex-dividend date is Thursday, March 15th. This represents a $2.28 annualized dividend and a dividend yield of 2.83%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s dividend payout ratio (DPR) is presently 59.77%.
In other news, Director Gayle E. Wilson sold 60,000 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $77.92, for a total transaction of $4,675,200.00. Following the completion of the sale, the director now owns 182,258 shares in the company, valued at approximately $14,201,543.36. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $74.64, for a total transaction of $1,119,600.00. Following the sale, the executive vice president now owns 70,988 shares of the company’s stock, valued at approximately $5,298,544.32. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 418,333 shares of company stock valued at $32,742,108. 1.30% of the stock is currently owned by company insiders.
GILD has been the topic of a number of research analyst reports. JPMorgan Chase & Co. set a $85.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Credit Suisse Group reissued a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a research report on Thursday, December 7th. Zacks Investment Research cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, December 27th. ValuEngine raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 8th. Finally, Argus cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and increased their price objective for the stock from $73.25 to $73.77 in a research report on Monday, November 13th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $87.04.
COPYRIGHT VIOLATION NOTICE: This article was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.chaffeybreeze.com/2018/02/20/burns-j-w-co-inc-ny-sells-1597-shares-of-gilead-sciences-inc-gild.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.